Gene · 79679
Papers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 2,409
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma. | Aging (Albany NY) | 2023 | 37211398 | PubTator, text mining | PubMed |
| PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest. | Aging (Albany NY) | 2023 | 37211383 | PubTator, text mining | PubMed |
| Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective. | Mol Cell Proteomics | 2023 | 37209814 | PubTator, text mining | PubMed |
| Elevated MPP6 expression correlates with an unfavorable prognosis, angiogenesis and immune evasion in hepatocellular carcinoma. | Front Immunol | 2023 | 37207207 | PubTator, text mining | PubMed |
| Investigation of the function of the novel tumor marker BEND5 in lung adenocarcinoma based on data mining and in vitro analysis. | J Thorac Dis | 2023 | 37197545 | PubTator, text mining | PubMed |
| Exploring animal models in oral cancer research and clinical intervention: A critical review. | Vet Med Sci | 2023 | 37196179 | PubTator, text mining | PubMed |
| Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. | Biomedicines | 2023 | 37189689 | PubTator, text mining | PubMed |
| Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer. | Diagnostics (Basel) | 2023 | 37189494 | PubTator, text mining | PubMed |
| Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. | Nat Commun | 2023 | 37185575 | PubTator, text mining | PubMed |
| A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2. | Hereditas | 2023 | 37170390 | PubTator, text mining | PubMed |
| Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma. | BMC Bioinformatics | 2023 | 37170221 | PubTator, text mining | PubMed |
| 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. | Commun Biol | 2023 | 37169941 | PubTator, text mining | PubMed |
| Comprehensive analysis of the oncogenic and immunological role of FAP and identification of the ceRNA network in human cancers. | Aging (Albany NY) | 2023 | 37166418 | PubTator, text mining | PubMed |
| Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects. | Cell Commun Signal | 2023 | 37158893 | PubTator, text mining | PubMed |
| Comprehensive analyses reveal the prognosis and biological function roles of chromatin regulators in lung adenocarcinoma. | Aging (Albany NY) | 2023 | 37155150 | PubTator, text mining | PubMed |
| Exploration of spatial heterogeneity of tumor microenvironment in nasopharyngeal carcinoma via transcriptional digital spatial profiling. | Int J Biol Sci | 2023 | 37151882 | PubTator, text mining | PubMed |
| Comprehensive prediction of immune microenvironment and hot and cold tumor differentiation in cutaneous melanoma based on necroptosis-related lncRNA. | Sci Rep | 2023 | 37147395 | PubTator, text mining | PubMed |
| Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review. | Front Oncol | 2023 | 37143952 | PubTator, text mining | PubMed |
| The generation, activation, and polarization of monocyte-derived macrophages in human malignancies. | Front Immunol | 2023 | 37143666 | PubTator, text mining | PubMed |
| Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma. | J Bone Oncol | 2023 | 37139222 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/papers?page=21